Internet Surveys and their Impact on Adherence to Topical Medication and Quality of Life in Patients with Rosacea

What we are studying

An investigator-blinded, prospective, 6 month study of subjects with persistent erythema associated with active rosacea will be conducted in 20 subjects aged 18 years and older. All subjects will receive standard-of-care brimonidine topical gel, 0.33% with instructions to apply it once daily per package insert. Adherence will be assessed using weekly internet surveys to document how often the medication is being used, as well as reminders about rosacea triggers and general use of brimonidine.

Who we are studying

  • Men and Women
  • Races:
    • White
  • Not Hispanic or Latino
  • Ages 18+

Eligibility Criteria

  • • Use of topical therapy for rosacea within 2 weeks of baseline. • Use of systemic corticosteroids within 4 weeks of baseline. • Subjects with severe cardiovascular disease or vascular insufficiency.

What is involved

  • Vital signs
  • Height
  • Weight
  • Urine pregnancy test

Compensation

None

Contact Information

Study Coordinator
Dermatology Clinical Studies
Email
dermadvertising@wakehealth.edu
Phone
336-716-3775
Principal Investigator
Steve Feldman, MD, PhD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.